Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors

Oncogene volume 22, pages 7862–7865 (2003)Cite this article

Abstract

The human Ras association domain family 1A (RASSF1A) gene, recently isolated from the lung and breast tumor suppressor locus 3p21.3, is highly methylated in primary lung, breast, nasopharyngeal and other tumors, and re-expression of RASSF1A suppresses the growth of several types of cancer cells. Epigenetic inactivation of RASSF1A by promoter hypermethylation is also important in the development of several human cancers. The methylation status of the promoter region of RASSF1A was analysed in primary brain tumors and glioma cell lines by methylation-specific polymerase chain reaction. In primary brain tumors, 25 of 46 (54.3%) gliomas and five of five (100%) medulloblastomas showed RASSF1A methylation. In benign tumors, only one of 10 (10%) schwannomas and two of 12 (16.7%) meningiomas showed RASSF1A methylation. The RASSF1A promoter region was methylated in all four glioma cell lines. RASSF1A was re-expressed in all methylated cell lines after treatment with the demethylating agent 5-aza-2′-deoxycytidine. Methylation of the promoter CpG islands of the RASSF1A may play an important role in the pathogenesis of glioma and medulloblastoma.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, Minna JD, Maher ER and Latif F . (2001). Oncogene, 20, 1509–1518.

  • Astuti D, Agathanggelou A, Honorio S, Dallol A, Martinsson T, Kogner P, Cummins C, Neumann HP, Voutilainen R, Dahia P, Eng C, Maher ER and Latif F . (2001). Oncogene, 20, 7573–7577.

  • Avet-Loiseau H, Venuat AM, Terrier-Lacombe MJ, Lellouch-Tubiana A, Zerah M and Vassal G . (1999). Br. J. Cancer, 79, 1843–1847.

  • Bayani J, Zielenska M, Marrano P, Kwan Ng Y, Taylor MD, Jay V, Rutka JT and Squire JA . (2000). J. Neurosurg., 93, 437–448.

  • Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M and Minna JD . (2001). J. Natl. Cancer Inst., 93, 691–699.

  • Byun DS, Lee MG, Chae KS, Ryu BG and Chi SG . (2001). Cancer Res., 61, 7034–7038.

  • Dammann R, Li C, Yoon JH, Chin PL, Bates S and Pfeifer GP . (2000). Nat. Genet., 25, 315–319.

  • Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, Angeloni D, Zbar B, Lerman MI, Stanbridge EJ, Minna JD, Protopopov A, Li J, Kashuba V, Klein G and Zabarovsky ER . (2001). Proc. Natl. Acad. Sci. USA, 98, 7504–7509.

  • Fults D, Pedone CA, Thomas GA and White R . (1990). Cancer Res., 50, 5784–5789.

  • Harada K, Toyooka S, Maitra A, Maruyama R, Toyooka KO, Timmons CF, Tomlinson GE, Mastrangelo D, Hay RJ, Minna JD and Gazdar AF . (2002). Oncogene, 21, 4345–4349.

  • Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB . (1996). Proc. Natl. Acad. Sci. USA, 93, 9821–9826.

  • Ishiuchi S, Tsuzuki K, Yoshida Y, Yamada N, Hagimura N, Okado H, Miwa A, Kurihara H, Nakazato Y, Tamura M, Sasaki T and Ozawa S . (2002). Nat. Med., 8, 971–978.

  • Jones PA and Laird PW . (1999). Nat. Genet., 21, 163–167.

  • Kanno H, Shuin T, Kondo K, Yamamoto I, Ito S, Shinonaga M, Yoshida M and Yao M . (1997). Cancer Res., 57, 1035–1038.

  • Kleihues P and Cavenee WK (eds.) (2000). Pathology and Genetics of Tumors of the Nervous System. IARC Press: Lyon, France.

    Google Scholar 

  • Kok K, Naylor SL and Buys CH . (1997). Adv. Cancer Res., 71, 27–92.

  • Lee MG, Kim HY, Byun DS, Lee SJ, Lee CH, Kim JI, Chang SG and Chi SG . (2001). Cancer Res., 61, 6688–6692.

  • Lo KW, Kwong J, Hui AB, Chan SY, To KF, Chan AS, Chow LS, Teo PM, Johnson PJ and Huang DP . (2001). Cancer Res., 61, 3877–3881.

  • Lusher ME, Lindsey JC, Latif F, Pearson AD, Ellison DW and Clifford SC . (2002). Cancer Res., 62, 5906–5911.

  • Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK and De Pinho RA . (2001). Genes Dev., 15, 1311–1333.

  • Maitra A, Wistuba II, Washington C, Virmani AK, Ashfaq R, Milchgrub S, Gazdar AF and Minna JD . (2001). Am. J. Pathol., 159, 119–130.

  • Mollerup S, Ryberg D, Hower A, Phillips DH and Haugen A . (1999). Cancer Res., 59, 3317–3320.

  • Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D, Morgan NV, Moch H, Richards FM, Kishida T, Yao M, Schraml P, Latif F and Maher ER . (2001). Cancer Res., 61, 7277–7281.

  • Tomizawa Y, Kohno T, Kondo H, Otsuka A, Nishioka M, Niki T, Yamada T, Maeshima A, Yoshimura K, Saito R, Minna JD and Yokota J . (2002). Clin. Cancer Res., 8, 2362–2368.

  • Toyooka S, Pass HI, Shivapurkar N, Fukuyama Y, Maruyama R, Toyooka KO, Gilcrease M, Farinas A, Minna JD and Gazdar AF . (2001). Cancer Res., 61, 5727–5730.

  • Vos MD, Ellis CA, Bell A, Birrer MJ and Clark GJ . (2000). J. Biol. Chem., 275, 35669–35672.

  • Yoon JH, Dammann R and Pfeifer GP . (2001). Int. J. Cancer, 94, 212–217.

  • Zabarovsky ER, Lerman MI and Minna JD . (2002). Oncogene, 21, 6915–6935.

Download references

Acknowledgements

We thank Ms Mitsue Maniwa and Ms Mayumi Umemura for technical assistance. This study was partly supported by grants from the Ministry of Education, Science, Sports and Culture, Japan.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Gunma University School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan

    Keishi Horiguchi, Masahiko Tosaka, Shogo Ishiuchi, Hideyuki Kurihara & Nobuhito Saito

  2. First Department of Internal Medicine, Gunma University School of Medicine, Maebashi, Gunma, 371-8511, Japan

    Yoshio Tomizawa & Masatomo Mori

Authors
  1. Keishi Horiguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshio Tomizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masahiko Tosaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shogo Ishiuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hideyuki Kurihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masatomo Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nobuhito Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Keishi Horiguchi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Horiguchi, K., Tomizawa, Y., Tosaka, M. et al. Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors. Oncogene 22, 7862–7865 (2003). https://doi.org/10.1038/sj.onc.1207082

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207082

Keywords

This article is cited by

Search

Advanced search

Quick links